4-N-(3-fluorophenyl)-4-N-methyl-6-[5-(1-methyl-1H-pyrazol-4-yl)-1H-pyrrolo[2,3-b]pyridin-3-yl]pyrimidine-2,4-diamine | 1374420-13-9

• 分子结构分类: 有机化合物 - 有机氮化合物
• 英文名称: 4-N-(3-fluorophenyl)-4-N-methyl-6-[5-(1-methyl-1H-pyrazol-4-yl)-1H-pyrrolo[2,3-b]pyridin-3-yl]pyrimidine-2,4-diamine
• 英文别名: 4-N-(3-fluorophenyl)-4-N-methyl-6-[5-(1-methylpyrazol-4-yl)-1H-pyrrolo[2,3-b]pyridin-3-yl]pyrimidine-2,4-diamine
• CAS: 1374420-13-9
• 化学式: C₂₂H₁₉FN₈
• 分子量: 414.445
• InChiKey: FSVAXGJNSLSHBN-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3
• 重原子数：
  31
• 可旋转键数：
  4
• 环数：
  5.0
• sp3杂化的碳原子比例：
  0.09
• 拓扑面积：
  102
• 氢给体数：
  2
• 氢受体数：
  7

文献信息

• 1H-Pyrrolo[2,3 b]pyridine derivatives
  申请人：Heinrich Timo

  公开号：US20130231519A1

  公开（公告）日：2013-09-05

  1H-Pyrrolo[2,3-b]pyridine compounds are inhibitors of cell proliferation/cell vitality and can be employed for the treatment of tumours.

  1H-Pyrrolo[2,3-b]pyridine化合物是细胞增殖/细胞活力的抑制剂，可用于治疗肿瘤。
• 1H-Pyrrolo[2,3-b]Pyridine Derivatives
  申请人：HEINRICH Timo

  公开号：US20140100221A1

  公开（公告）日：2014-04-10

  1H-Pyrrolo[2,3-b]pyridine compounds are inhibitors of cell proliferation/cell vitality and can be employed for the treatment of tumours.

  1H-Pyrrolo[2,3-b]pyridine化合物是细胞增殖/细胞活力的抑制剂，可用于肿瘤治疗。
• 1-H-Pyrrolo[2,3-b]Pyridine Derivatives
  申请人：Merck Patent GmbH

  公开号：US20140371215A1

  公开（公告）日：2014-12-18

  1H-Pyrrolo[2,3-b]pyridine compounds are inhibitors of cell proliferation/cell vitality and can be employed for the treatment of tumours.

  1H-Pyrrolo[2,3-b]pyridine化合物是细胞增殖/细胞生命力的抑制剂，可用于肿瘤的治疗。
• 1H-PYRROLO[2,3-B]PYRIDINDERIVATE
  申请人：Merck Patent GmbH

  公开号：EP2635574B1

  公开（公告）日：2014-09-10
• COMPOSITIONS AND METHODS TO IMPROVE THE THERAPEUTIC BENEFIT OF SUBOPTIMALLY ADMINISTERED CHEMICAL COMPOUNDS INCLUDING SUBSTITUTED NAPHTHALIMIDES SUCH AS AMONAFIDE FOR THE TREATMENT OF IMMUNOLOGICAL, METABOLIC, INFECTIOUS, AND BENIGN OR NEOPLASTIC HYPERPROLIFERATIVE DISEASE CONDITIONS
  申请人：BROWN Dennis M.

  公开号：US20160067241A1

  公开（公告）日：2016-03-10

  The present invention describes methods and compositions for improving the therapeutic efficacy of therapeutic agents previously limited by suboptimal therapeutic performance by either improving efficacy as monotherapy or reducing side effects. Such methods and compositions are particularly applicable to naphthalimides such as amonafide or analogs, derivatives, or prodrugs thereof.